Table 2.
Outcomes | ABE + FUL | RIB + FUL | PAL + FUL | FUL |
---|---|---|---|---|
LYs | 4.09 | 4.29 | 3.65 | 3.20 |
QALYs | 2.36 | 2.33 | 1.92 | 1.68 |
Cost, $ | $541,890 | $541,372 | $441,194 | $281,306 |
Incremental cost | / | $518 | $100,696 | $260,584 |
Incremental QALYs | / | 0.03 | 0.44 | 0.68 |
Incremental cost per LY, $ | / | Dominated | $229,689 | $291,323 |
Incremental cost per QALY, $ | / | $19,314 | $229,039 | $381,450 |
LYs, life years; QALYs, quality-adjusted life years; ABE, abemaciclib; RIB, ribociclib; PAL, palbociclib; FUL, fulvestrant.